Avita Medical (NASDAQ:RCEL) Announces Quarterly Earnings Results, Hits Estimates

Posted by Stanley Muller on May 15th, 2026

Avita Medical (NASDAQ:RCEL – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35), Zacks reports. The firm had revenue of $19.25 million for the quarter, compared to analyst estimates of $18.30 million.

Here are the key takeaways from Avita Medical’s conference call:

AVITA reported Q1 2026 revenue of $19.3 million, up 4% year over year and about 10% sequentially, and reiterated full-year guidance of $80 million to $85 million.
RECELL utilization is recovering as reimbursement uncertainty normalizes, with all 7 Medicare Administrative Contractors now publishing payment rates and management saying all are effectively reimbursing.
Cohealyx is showing early commercial traction, including more ordering accounts and repeat usage, while interim study data showed about a 20-day reduction to graft readiness versus benchmark.
The company signed a new long-term BARDA agreement that provides modest recurring readiness revenue and supports AVITA’s role in burn emergency preparedness.
Operating expenses fell 11% year over year to $24.5 million, and management said the cost structure is now stabilized; however, gross margin declined to 81.7% due to product mix and inventory reserves.

Avita Medical Trading Up 6.5%

RCEL stock traded up $0.29 during mid-day trading on Friday, hitting $4.65. 945,983 shares of the company were exchanged, compared to its average volume of 233,690. Avita Medical has a 1-year low of $3.22 and a 1-year high of $7.12. The stock has a market capitalization of $142.97 million, a PE ratio of -2.65 and a beta of 1.90. The business has a 50 day simple moving average of $4.39 and a 200-day simple moving average of $4.05.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RCEL. Wall Street Zen downgraded shares of Avita Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 2nd. Northland Securities initiated coverage on Avita Medical in a research report on Thursday, March 5th. They set an “outperform” rating and a $10.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avita Medical in a research report on Friday, March 27th. Lake Street Capital raised Avita Medical from a “hold” rating to a “buy” rating and increased their price objective for the company from $3.50 to $6.00 in a report on Friday. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Avita Medical in a research report on Wednesday, April 8th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.25.

Get Our Latest Analysis on Avita Medical

Hedge Funds Weigh In On Avita Medical

A number of large investors have recently made changes to their positions in the company. Deutsche Bank AG boosted its stake in Avita Medical by 1,351.5% in the 4th quarter. Deutsche Bank AG now owns 7,896 shares of the company’s stock valued at $27,000 after purchasing an additional 7,352 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Avita Medical by 122.2% during the fourth quarter. Russell Investments Group Ltd. now owns 8,047 shares of the company’s stock worth $28,000 after buying an additional 4,425 shares in the last quarter. Aristides Capital LLC bought a new stake in shares of Avita Medical in the fourth quarter valued at about $48,000. The Manufacturers Life Insurance Company bought a new stake in shares of Avita Medical in the second quarter valued at about $58,000. Finally, Wells Fargo & Company MN grew its stake in shares of Avita Medical by 98.5% in the fourth quarter. Wells Fargo & Company MN now owns 18,832 shares of the company’s stock valued at $65,000 after acquiring an additional 9,345 shares in the last quarter. Institutional investors own 27.66% of the company’s stock.

Avita Medical Company Profile

(Get Free Report)

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.